• Damien J Ellens and Robert M Levy.
• Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Ill. 60611, USA.
• Prog Neurol Surg. 2011 Jan 1;24:109-17.

AbstractExtremely high prevalence among general population along with the high percentage of treatment-refractory cases makes migraine headaches one of the potentially largest indications for neuromodulation. Cranial peripheral nerve stimulation targeting the occipital nerve(s) alone or in combination with others appears to be both safe and efficacious for the treatment of medically intractable migraine headaches. Although initial reports of occipital nerve stimulation for migraine headaches were very encouraging, this clinical benefit was not clearly confirmed in larger-scale prospective randomized trials. Moreover, the exact mechanism of neuromodulation effect in migraine treatment remains unclear. Significant further investigation needs to be performed to optimize our knowledge concerning patient selection, stimulation targets and parameters and device programming, and further improve clinical results. At present, neurostimulation for migraine headache pain is performed in the United States on an 'off-label' basis, but based upon our experience and the increasing evidence in the medical literature, we look forward to its approval by the FDA in the near future so that patients suffering from severe, medically intractable headache pain may gain access to these potentially important therapies.Copyright © 2011 S. Karger AG, Basel.

13 keywords...

hide…